Japan Point-of-Care Diagnostics Market to Reach US$ 1.93 Billion by 2033, Led by Infectious Disease Testing Segment | DataM Intelligence

Leander, Texas and TOKYO, Japan - Jan.05.2026 "The Japan Point-of-Care Diagnostics Market reached US$ 832.04 million in 2024 and is expected to reach US$ 1,925.62 million by 2033, growing with a CAGR of 9.8% during the forecast period 2025-2033."

The Japan Point-of-Care Diagnostics Market is driven by rapid advancements in diagnostic technologies, an aging population requiring decentralized care, rising prevalence of chronic and infectious diseases, and Japan's leadership in precision engineering for portable devices. The shift toward faster, accurate testing in hospitals, clinics, home care, and rural settings is accelerating the adoption of POC tools for glucose monitoring, infectious diseases, cardiac markers, and more, supported by innovations in microfluidics, biosensors, and molecular diagnostics.

➠ Download Your Sample Report Instantly - Corporate Email ID Required for Priority Access: https://www.datamintelligence.com/download-sample/japan-point-of-care-diagnostics-market?praneetha

☛ Japan Recent Industry Developments :
✅ December 2025
Sysmex Corporation launched a next-generation point-of-care hematology analyzer designed for rapid testing in clinics and emergency settings. The system improves turnaround time and diagnostic accuracy for decentralized healthcare environments.

✅ November 2025
Fujifilm Healthcare expanded its point-of-care diagnostic portfolio with a compact immunoassay testing platform for infectious disease screening. The launch supports faster clinical decision making in outpatient and community healthcare facilities across Japan.

✅ October 2025
Horiba Medical Japan introduced a portable clinical chemistry analyzer optimized for small hospitals and primary care centers. The device enhances accessibility to real-time diagnostic testing and supports Japan's growing demand for decentralized healthcare solutions.

☛ Core Catalysts Behind Market Growth:
Rapid advancements in point-of-care diagnostics, including miniaturization of equipment and portable devices for real-time data in clinical and non-clinical settings.

Increasing need for rapid and accurate detection of infectious diseases, driven by early diagnosis, decentralized testing, and concerns over antimicrobial resistance.

Government efforts to enhance diagnostic capabilities and preparedness in response to public health threats.

Technological innovations from Japan's leadership in electronics, robotics, and precision engineering, enabling compact and efficient diagnostic devices.

➠ Get Customization in the Report as per Your Requirements: https://www.datamintelligence.com/customize/japan-point-of-care-diagnostics-market?praneetha

☛ Market Segmentation :
By Product :
Infectious disease testing products lead the market with 31% share, driven by strong demand for rapid testing of respiratory, gastrointestinal, and emerging infectious diseases in hospitals and clinics. Blood glucose products hold 24% share, supported by Japan's aging population and high prevalence of diabetes requiring frequent monitoring. Blood gas and electrolyte products account for 13% share, widely used in emergency and critical care settings for rapid clinical decision making. Urinalysis products capture 10% share, benefiting from routine screening and chronic disease monitoring. Hematology testing products represent 8% share, driven by point-of-care blood count assessments. Pregnancy and fertility testing products hold 6% share, supported by home based and clinic based testing. Tumor and cancer profiling products account for 4% share, reflecting growing adoption of rapid oncology diagnostics. Drug of abuse testing products and other product types collectively hold 4% share, used in occupational health, law enforcement, and specialty clinical settings.

By Technology :
Lateral flow assays dominate with 36% share, owing to their low cost, ease of use, and rapid turnaround time in infectious disease and pregnancy testing. Immunoassays hold 28% share, driven by their accuracy and widespread use in cardiac markers, hormones, and infectious disease diagnostics. Molecular diagnostics account for 18% share, supported by rising demand for high-sensitivity pathogen detection and genetic testing at the point of care. Microfluidics represent 12% share, benefiting from miniaturization trends and integration into compact diagnostic platforms. Other technologies capture 6% share, including biosensors and emerging lab on chip solutions.

By Application :
Infectious diseases represent the largest application segment with 33% share, driven by the need for rapid diagnosis and containment of viral and bacterial infections. Cardiology holds 18% share, supported by point-of-care testing for cardiac markers such as troponin in emergency care. Oncology accounts for 14% share, reflecting increasing use of rapid cancer screening and monitoring tools. Endocrinology captures 13% share, largely driven by diabetes and thyroid disorder testing. Hematology represents 9% share, used for rapid blood parameter assessments. Neurology accounts for 6% share, supported by testing for biomarkers related to stroke and neurodegenerative disorders. Drug testing and other applications collectively hold 7% share, including toxicology and specialty diagnostics.

By End User :
Hospitals and clinics dominate with 49% share, supported by high patient inflow, advanced diagnostic infrastructure, and strong adoption of rapid testing solutions. Diagnostic laboratories account for 21% share, driven by decentralized testing and satellite lab operations. Home care settings hold 18% share, reflecting growing demand for self-testing kits and remote patient monitoring solutions among elderly and chronic disease patients. Ambulatory surgery centers (ASCs) capture 12% share, supported by the need for rapid preoperative and postoperative diagnostic testing in outpatient surgical procedures.

Competitive Landscape:
The market features intense competition among global diagnostics giants and local innovators focused on regulatory-compliant, high-precision POC solutions.

Abbott Laboratories - Commands an estimated 16% share, leading with strong portfolio in rapid testing, glucose monitoring, and infectious disease diagnostics.

Roche Diagnostics - Holds about 14% market share, prominent in molecular and professional POC systems.

Siemens Healthineers - Captures around 12% share, trusted for integrated blood gas, cardiology, and critical care analyzers.

Becton, Dickinson and Company (BD) - Maintains approximately 10% share through infectious disease and specimen collection innovations.

QIAGEN - Secures roughly 9% share with syndromic and molecular POC platforms.

Other Key Players: Quidel Corporation, Trinity Biotech, BioMérieux SA, Danaher Corporation, SEKISUI MEDICAL CO., LTD., Sysmex Corporation.

➠ Purchase this report before year-end and unlock an exclusive 30% discount :
Buy Now & Unlock 360° Market Intelligence : https://www.datamintelligence.com/buy-now-page?report=japan-point-of-care-diagnostics-market?praneetha

(Purchase 2 or more Reports and get 50% Discount)

☛ Regional Analysis (Japan-Focused) :
The market shows concentration in urban centers with variations across regions :

Kanto (including Tokyo) : Leads with highest demand, driven by advanced hospitals, high population density, and innovation hubs.

Kansai (Osaka, Kyoto) : Strong in clinical and research applications, supported by major medical institutions.

Hokkaido & Tohoku : Growing demand for POC in rural and elderly populations requiring quick diagnostics.

Chubu & Kyushu : Supported by manufacturing and aging demographics, with focus on chronic disease management.

Overall national growth fueled by addressing rural disparities and urban chronic care needs.

➠ Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription?praneetha

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Market Access Snapshots
✅ Emerging Risks & Market Volatility Analysis
✅ Quarterly Updated Reports
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Company Name: DataM Intelligence 4Market Research LLP
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com/

DataM Intelligence is a global Market Research and Consulting firm providing comprehensive business insights and end-to-end solutions from research to consulting. We deliver actionable intelligence across 6,300+ reports spanning 40+ domains, empowering over 200 companies in 50+ countries. Our focus is on enabling clients to make data-driven decisions through robust methodologies, strategic foresight, and real-time market intelligence.

This release was published on openPR.